NEUPHORIA THERAPEUTICS INC.
Last · NasdaqGM$3.24-0.15 (-4.42%)close · yahoo · 16h ago
Market cap$17.53M5.4M sh
P/E · TTM-1.1fwd -1.3 · eps -2.97 · loss
Beta—vs S&P 500
Div yield0.00%annual · TTM
52w range
$3.19$17.19
Volume46.0Ksession
| Revenue | $1.2M |
|---|---|
| Operating income | $-16.5M |
| Net income | $-13.5M |
| Operating margin | -1401.1% |
| Net margin | -1145.7% |
| Return on equity | -54.7% |
| Period | 2026 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-09-18
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
Red flags
- Sbc Revenue High — SBC/Revenue 29.9%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -1145.7%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -1052.1%
- Cash Runway Low — Cash runway ~1.6 years
- Accumulated Deficit High — Accumulated deficit / equity 780%
Press & signals
- GlobeNewswire
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
Documents
FormReporting forFiledFlags